Compare DMAC & SVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMAC | SVC |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.1M | 349.6M |
| IPO Year | 2018 | 1995 |
| Metric | DMAC | SVC |
|---|---|---|
| Price | $5.97 | $1.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $15.50 | $2.50 |
| AVG Volume (30 Days) | 160.6K | ★ 19.5M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.60% |
| EPS Growth | N/A | ★ 26.95 |
| EPS | ★ N/A | N/A |
| Revenue | $500,000.00 | ★ $1,814,838,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.48 | $1.13 |
| 52 Week High | $10.42 | $3.08 |
| Indicator | DMAC | SVC |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 46.01 |
| Support Level | $5.71 | $1.13 |
| Resistance Level | $6.29 | $1.62 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 22.47 | 69.51 |
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.